Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neoleukin Therapeutics, Inc. - Common Stock (NQ:NLTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neoleukin Therapeutics, Inc. - Common Stock

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)
From Brodsky & Smith LLC
Via GlobeNewswire
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Neurogene and Neoleukin Announce Definitive Merger Agreement
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells 
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.